

Allianz All China Equity

Monthly commentary

- The Fund aims at long-term capital growth by investing in onshore and offshore People's Republic of China ("PRC"), Hong Kong and Macau equity markets in accordance with environmental and social characteristics. The Fund aims to achieve an outperformance (i.e. achieve a higher Environment, Social and Governance ("ESG") score) of the Fund's weighted average ESG score compared to weighted average ESG score of Fund's benchmark index by the adoption of the ESG Score Strategy. The Fund does not constitute as an ESG fund pursuant to the SFC's circular issued on 29 June 2021.
- The Fund is exposed to significant risks of investment/general market, country and region, emerging market, company-specific, currency (such as exchange controls, in particular RMB), and the adverse impact on RMB share classes due to currency depreciation.
- The Fund may invest in the China A-Shares market directly via the Stock Connect or other foreign access regimes and/or other permitted means and/or indirectly through all eligible instruments and thus is subject to the associated risks (including quota limitation, change in rule and regulations, repatriation of the Fund's monies, trade restrictions, China market volatility and uncertainty, potential clearing and/or settlement difficulties, change in economic, social and political policy in PRC and Mainland China tax risks).
- The Fund is exposed to risks relating to ESG Score Strategy investment (such as foregoing opportunities to buy certain securities when it might otherwise be advantageous to do so, selling securities when it might be disadvantageous to do so, and/or reducing risk diversifications compared to broadly based funds) which may result in the Fund being more volatile and have adverse impact on the performance of the Fund and consequently adversely affect an investor's investment in the Fund.
- The Fund may invest in financial derivative instruments ("FDI") which may expose to higher leverage, counterparty, liquidity, valuation, volatility, market and over the counter transaction risks. The Fund's net derivative exposure may be up to 50% of the Fund's net asset value.
- This investment may involve risks that could result in loss of part or entire amount of investors' investment.
- In making investment decisions, investors should not rely solely on this material.

Note: Dividend payments may, at the sole discretion of the Investment Manager, be made out of the Fund's capital or effectively out of the Fund's capital which represents a return or withdrawal of part of the amount investors originally invested and/or capital gains attributable to the original investment. This may result in an immediate decrease in the NAV per share and the capital of the Fund available for investment in the future and capital growth may be reduced, in particular for hedged share classes for which the distribution amount and NAV of any hedged share classes (HSC) may be adversely affected by differences in the interests rates of the reference currency of the HSC and the base currency of the Fund.

What Happened in March

The Fund lagged the benchmark in March. Stock selection in the Consumer Discretionary sector was the main detractor.

At a stock level, a detractor last month was Zijin Mining*, a leading mining group engaged in the exploration and production of gold, copper and other base metals. The share price pullback was largely due to profit taking after a strong run earlier in the year, alongside a pullback in gold and copper prices. Over the longer term, we remain constructive on the outlook given Zijin Mining's globally diversified, low-cost resource base and strong leverage to structurally higher demand for copper and gold driven by energy transition, electrification and geopolitical uncertainty.

Conversely, a key contributor was a clinical-stage biotech company with a focus on oncology. The company announced encouraging updates on its product pipeline development, helping to reinforce confidence in both depth and quality of its research and development (R&D) platform. The company is building out an increasingly diverse product pipeline with a number of promising new drugs at final stages of clinical trials. Domestic sales are ramping up quickly and we believe it is

likely the company will form a partnership with a global pharmaceutical company to support sales and marketing activity outside China.

Outlook and Strategy

China equities were weaker in March with both onshore and offshore markets reacting to events in the Middle East, before stabilising towards the month-end. Indeed, year-to-date, China A-shares have been notably resilient, continuing their outperformance of the S&P 500 and also demonstrating relatively low correlations with global equities.

Stability has also been a feature of China's fixed income and currency markets. China's 10-year government bond yield remains just above 1.8%, almost unchanged from levels before the Middle East conflict began. The renminbi has appreciated against the US dollar year-to-date and was little changed during March.

The resilience of China's financial markets reflects a number of factors, not least that China's diversified economy is relatively well positioned for extreme scenarios, especially after years of building self-reliance across energy, food, and supply chains. As such, while sell-side analysts have been trimming China gross domestic product (GDP) growth expectations for this year, there have been greater reductions in the outlook for most other global economies.

In terms of energy supply, while China is still quite heavily dependent on fossil fuels, it has looked to reduce exposure to oil and gas, and also to hedge this via pipelines from Russia and Central Asia. Less than 10% of energy in China is exposed to the Gulf. Indeed, over a sustained period, China has been developing a technology stack focused on electricity and ways of generating, using and storing energy. Whereas in 2010, electricity accounted for around 18% of energy consumption, today it is above 30%. Solar and wind have increased their share of electricity from around 1% previously to about 20% today.

Another feature of China equity markets is that energy security has been a strong theme benefitting a number of energy, renewables, power grid, energy storage and electric vehicle (EV) companies. Looking ahead, the recent experience of surging energy prices and fuel shortages, combined with heightened geopolitical uncertainty, will likely prompt more countries to prioritise energy security.

This will involve activities including building nuclear power plants, increasing renewable energy installations, accelerating EV adoption, and further electrifying economies. As China dominates many of these sectors, it stands to gain from this global shift over the longer term.

The Middle East conflict has also masked another artificial intelligence (AI) development milestone in China – the rise of agentic AI. If the "DeepSeek moment" was a game changer, which proved China was capable of producing globally competitive AI models, the recent surge of token usage – a key measure of model capacity and real-world demand – highlights how AI deployment in China is rapidly accelerating. We increasingly see a buildout of China-centric AI infrastructure, including chips, data centres, models and applications, which is set to become the backbone of future industrial growth supporting a range of areas such as autonomous driving, humanoid robotics and biotech.

In summary, in such highly unpredictable and uncertain times, we see China equities – and A-shares in particular – providing both valuable portfolio diversification as well as idiosyncratic growth opportunities.

We have not changed portfolio positioning significantly in reaction to events in the Middle East but rather have made some changes at the margin. For example, we initiated a new position in the energy storage and renewables space. We also built exposure to a leading data centre operator that provides critical infrastructure supporting areas such as cloud computing and other AI workloads.

At month-end, the Fund has around 43% in China A-shares. The portfolio continues to have relatively close-to-benchmark sector allocations, so that stock selection remains the key relative performance driver. At month-end, the largest sector overweight is Industrials (+4.2%), while the largest underweight is Consumer Discretionary (-3.1%).

Connect with Us

hk.allianzgi.com

+852 2238 8000

Search more





Like us on Facebook [安聯投資 – 香港](#)



Connect on LinkedIn [Allianz Global Investors](#)



Subscribe to YouTube channel [安聯投資](#)

Source: Bloomberg, Allianz Global Investors, as of 31 March 2026 unless otherwise stated.

*The information above is provided for the purpose to demonstrate the Fund's investment strategy only, it should not be considered a recommendation nor investment advice to buy or sell any shares of securities. There is no assurance that any securities discussed herein will remain in the Fund at the time you receive this document. Any securities mentioned (above) is for illustrative purposes only. It should not be considered as an investment advice, or a recommendation to buy or sell any particular security or strategy.

Information herein is based on sources we believe to be accurate and reliable as at the date it was made. We reserve the right to revise any information herein at any time without notice. No offer or solicitation to buy or sell securities and no investment advice or recommendation is made herein. In making investment decisions, investors should not rely solely on this material but should seek independent professional advice.

Investment involves risks, in particular, risks associated with investment in emerging and less developed markets. Past performance is not indicative of future performance. Investors should read the offering documents for further details, including the risk factors, before investing. This material and website have not been reviewed by the Securities and Futures Commission of Hong Kong. Issued by Allianz Global Investors Asia Pacific Limited.

The Fund is not domiciled in the Macao Special Administrative Region ("Macao SAR"), and its regulatory standards may differ from those applicable in the Macao SAR.